Most information on IFN gene signatures in MS has, indeed, identified them mainly as IFN-β treatment-related biomarkers in human peripheral blood mononuclear cells (PBMC) of MS patients analyzed before and after IFN-β therapy, e.g., in Malhotra et al. (15) and other references. The gene discussed is IFNB1; the disease is myeloid sarcoma.